Stockreport

Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

Kairos Pharma, Ltd.  (KAPA) 
PDF Company recognized for advancing ENV-105, a first-in-class resistance-modulating antibody for metastatic castration-resistant prostate cancer LOS ANGELES--(BUSINESS W [Read more]